Mary Scholand, MD
Enriched profileAssociate Professor of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine; Director, Interstitial Lung Disease Clinic · University of Utah Health
Mary Scholand is Associate Professor of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine; Director, Interstitial Lung Disease Clinic at University of Utah Health. OpenAlex indexes 163 publications with 7,720 citations (h-index 44); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Mary Beth Scholand, MD, is Associate Professor of Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine at University of Utah Health / Spencer Fox Eccles School of Medicine, Salt Lake City, UT. The public record shows 163 publications with 7,720 citations (h-index 44), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases, Chronic Obstructive Pulmonary Disease (COPD) Research. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 11 companies.
- Most recent indexed publication: 2024 · Annals of internal medicine
- Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 76.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
Sponsor: University of Alabama at Birmingham
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: Rein Therapeutics
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Sponsor: Avalyn Pharma Inc.
Industry payments
Updated 14 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year202534 payments$35,891openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year202531 payments$30,833openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202518 payments$19,843openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58.2%Kinase inhibitor28.5%Ofev100%Part D≥46 patientsPyridone26.5%Pirfenidone95%Esbriet5%Part D<11 patients+ 1 more class in this area
Respiratory
20.7%Corticosteroid9.5%Fluticasone Propionate21%Breo Ellipta20%Symbicort18%Trelegy Ellipta16%Breztri Aerosphere13%Dulera11%Part D<11 patientsbeta2-Adrenergic Agonist7.6%Albuterol Sulfate Hfa85%Ventolin Hfa15%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
16.2%Corticosteroid11.9%Prednisone100%Part D≥43 patientsProton pump inhibitor4.3%Omeprazole76%Pantoprazole Sodium24%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Annals of internal medicine
Article2024 - Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
American journal of respiratory and critical care medicine
Guideline2024 - Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.
The European respiratory journal
Clinical Trial2021 - Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.
The European respiratory journal
Article2020
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mary-beth-scholand-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
rarediseaseadvisor.com/podcasts/dr-mary-beth-scholand-chest-three-lakes-foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rarediseaseadvisor.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- Internal Medicine Residency
Washington University/Barnes-Jewish Hospital/St. Louis Children's Hospital Consortium
1993provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗ - Board Certified
Pulmonary Disease (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Director
Interstitial Lung Disease Clinic, University of Utah Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthcare.utah.edu ↗ - Clinical Research Compliance Director
Department of Internal Medicine, University of Utah
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.utah.edu ↗ - Faculty Mentor
Office of Undergraduate Research, University of Utah
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →our.utah.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →google.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rarediseaseadvisor.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital